FDA — authorised 26 June 2020
- Application: NDA208232
- Marketing authorisation holder: CHIESI
- Local brand name: MYCAPSSA
- Indication: CAPSULE, DELAYED RELEASE — ORAL
- Status: approved
🇺🇸 octreotide capsules in United States
FDA authorised octreotide capsules on 26 June 2020
Marketing authorisation
octreotide capsules in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Endocrinology approved in United States
Frequently asked questions
Is octreotide capsules approved in United States?
Yes. FDA authorised it on 26 June 2020.
Who is the marketing authorisation holder for octreotide capsules in United States?
CHIESI holds the US marketing authorisation.